Cellular Biomedicine Group, Inc. (CBMG): Price and Financial Metrics
CBMG Price/Volume Stats
| Current price | $19.75 | 52-week high | $19.75 |
| Prev. close | $19.75 | 52-week low | $11.48 |
| Day low | $19.73 | Volume | 171,900 |
| Day high | $19.75 | Avg. volume | 129,776 |
| 50-day MA | $18.65 | Dividend yield | N/A |
| 200-day MA | $17.03 | Market Cap | 384.69M |
CBMG Stock Price Chart Interactive Chart >
Cellular Biomedicine Group, Inc. (CBMG) Company Bio
Cellular Biomedicine Group develops treatments for cancerous and degenerative diseases in China. The company was incorporated in 2001 and is based in Palo Alto, California.
Latest CBMG News From Around the Web
Below are the latest news stories about Cellular Biomedicine Group Inc that investors may wish to consider to help them evaluate CBMG as an investment opportunity.
Cellular Biomedicine Group, Inc. Stockholders Approve MergerCellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company's special meeting of stockholders held today, its stockholders approved the proposal to adopt the previously announced Agreement and Plan of Merger, dated as of August 11, 2020 (the "Merger Agreement"), by and among CBMG, CBMG Holdings ("Parent") and CBMG Merger Sub Inc., a wholly-owned subsidiary of Parent ("Merger Sub"). The Merger Agreement provides for the merger of Merger Sub with and into CBMG (the "Merger"), with CBMG surviving the Merger as a wholly-owned subsidiary of Parent. Upon the closing of the Merger, CBMG's stockholders will receive $19.75 per share in cash for each share of CBMG common stock they own. |
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed MergerROCKVILLE, Md. and SHANGHAI , Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG ) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that leading proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services Inc. have both recommended that the Company's stockholders vote FOR the proposal to adopt the definitive merger agreement that provides for the acquisition of CBMG for $19.75 in cash per share of common stock in a going private transaction (the "merger proposal"). The Company will hold a special meeting of the stockholders on February 8, 2021 at 9:00 a.m. Eastern time , at 9605 Medical Center Drive, Sui... |
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates UROV, WTRE, CBMG, NAV; Shareholders Are Encouraged to Contact the FirmNEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sumitovant Biopharma Ltd. for $16.25 per share. If you are an Urovant shareholder, click here to learn more about your rights and options. Watford Holdings Ltd. (NASDAQ: WTRE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Arch Capital Group Ltd. for $35.00 per share. If you are a Watford shareholder, click here to learn more about your rights and options. Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concern... |
Lifshitz Law Firm, P.C. Announces Investigation of CBMG, HMSY, UROV, and WDRNEW YORK, NY / ACCESSWIRE / January 18, 2021 / Lifshitz Law Firm, P.:Cellular Biomedicine Group, Inc. |
ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, CGIX, UROVNEW YORK, Jan. 16, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. If you are a Cellular Biomedicine shareholder, click here to learn more about your rights and options. Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with StemoniX, Inc. Under the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX... |
CBMG Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 16.31% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 13.18% |
| 2019 | -8.04% |
Continue Researching CBMG
Want to see what other sources are saying about Cellular Biomedicine Group Inc's financials and stock price? Try the links below:Cellular Biomedicine Group Inc (CBMG) Stock Price | Nasdaq
Cellular Biomedicine Group Inc (CBMG) Stock Quote, History and News - Yahoo Finance
Cellular Biomedicine Group Inc (CBMG) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...